Skip to main content
. 2026 May 20;16:1847327. doi: 10.3389/fonc.2026.1847327

Table 1.

Patient characteristics of individuals with operable breast cancer or asymptomatic carriers of BRCA1 pathogenic variants.

Age at genetic testing (y.o.) Age at diagnosis of breast cancer (y.o.) Stage at diagnosis Subtype Breast surgery (y.o.): right/left Breast reconstruction: right/left RRSO (y.o.)
1 25 (−) (−) (−) (−)/(−) (−)/(−) (−)
2 37 37 IIIC ER+/HER2− CRRM (37)/mastectomy (37) (−)/(−) 39
3 38 38 I ER+/HER2− (−)/breast conserving surgery (38) (−)/(−) (−)
4 38 38 IIA ER+/HER2− CRRM (40)/mastectomy (38) (−)/(−) 39
5 45 41 IIA ER+/HER2− (−)/mastectomy (41) (−)/(−) (−)
45 45 I ER−/HER2− Mastectomy (45)/(−) (−)/(−) 45
6 47 47 0 ER+ CRRM (47)/nipple-sparing mastectomy (47) (+)/(+) 47
7 51 51 IIA ER−/HER2− (−)/mastectomy (52) (−)/(−) (−)
8 53 53 IIA ER+/HER2− CRRM(53)/mastectomy(53) (−)/(−) 54
9 63 (−) (−) (−) (−)/(−) (−)/(−) (−)

Case 5, who underwent genetic testing at age 45, was a single individual with a history of metachronous bilateral breast cancer.

RRSO, risk-reducing salpingo-oophorectomy; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; CRRM, contralateral risk-reducing mastectomy.